专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2019227230A1 NON-DESTRUCTIVE SAMPLING SYSTEM AND METHOD FOR QUALITY ASSESSMENT OF BLOOD PRODUCTS, AND SAMPLING SYSTEMS THEREFOR 审中-公开
公开(公告)号：WO2019227230A1
公开(公告)日：2019-12-05
申请号：PCT/CA2019/050758
申请日：2019-05-31
申请人： CANADIAN BLOOD SERVICES
发明人： SCHUBERT, Peter , MCTAGGART, Ken
IPC分类号： G01N1/10 , B65D30/10 , B65D33/36 , G01N1/20
摘要： There is provided a method of sampling an aliquot of blood products from a main container containing the blood products to be sampled. The method includes providing a sample container that is rectangular-shaped and has a length-over- width (L/W) ratio of at least that of the main container, and fluidly connecting the a sample container to the main container, transferring the aliquot of the blood products from the main container to the sample container, and forming an air bubble in the sample container by introducing a volume of air into the sample container with the aliquot of the blood products. The volume of air forming the air bubble corresponds to at least about 5% of a volume of the aliquot of the blood products. A sampling bag and a sampling system are disclosed.

2. 发明申请

WO2019075523A1 METHOD 审中-公开
公开(公告)号：WO2019075523A1
公开(公告)日：2019-04-25
申请号：PCT/AU2018/051136
申请日：2018-10-19
申请人： CSL LTD. , CANADIAN BLOOD SERVICES
发明人： LAZARUS, Alan , KAESERMANN, Fabian , KOERNIG, Sandra , CROW, Andrew
IPC分类号： C07K16/28 , C07K16/34 , C07K16/42 , A61P37/06 , A61K39/395
摘要： The invention relates to an antibody to a red blood cell for use in treating or preventing an inflammatory disorder, and to methods of treating or preventing an inflammatory disorder comprising administering to a subject in need thereof a therapeutically effective amount of an antibody to a red blood cell.

3. 发明申请

WO2014008608A1 ACELLULAR PRO-TOLEROGENIC COMPOSITIONS AND PROCESS FOR MAKING SAME 审中-公开
公开(公告)号：WO2014008608A1
公开(公告)日：2014-01-16
申请号：PCT/CA2013/050543
申请日：2013-07-12
申请人： CANADIAN BLOOD SERVICES
发明人： SCOTT, Mark D. , WANG, Duncheng , TOYOFUKU, Wendy M.
IPC分类号： A61K35/14 , A61K31/7105 , A61K47/30 , A61P37/02 , C12N5/078 , C12N5/0783
CPC分类号： A61K35/17 , A61K9/0019 , A61K35/00 , A61K35/14 , A61K39/0008 , A61K39/001 , A61K47/48215 , A61K47/48776 , A61K47/60 , A61K47/6901 , A61K2035/122 , A61K2035/124 , A61K2039/515 , A61K2039/577 , C12N5/0637 , C12N5/0638 , C12N15/113 , C12N2310/141 , C12N2500/50 , C12N2501/00 , C12N2501/65 , C12N2502/1114
摘要： This invention relates to pro-tolerogenic preparations capable of increasing the level of regulatory T cells (Treg) and/or decreasing the level of pro-inflammatory T cells (Th17) to induce anergy or immune tolerance. The pro-tolerogenic preparation is enriched in at least one species of miRNAs and is obtained by contacting two allogeneic leukocyte populations wherein at least one of the two populations is modified with a low-immunogenic biocompatible polymer. Acellular pro-tolerogenic compositions, process for making such composition as well as therapeutic uses of such compositions are also provided.
摘要翻译：本发明涉及能够增加调节性T细胞（Treg）的水平和/或降低促炎T细胞（Th17）的水平以诱导无能或免疫耐受性的耐容性制剂。致精原性制剂富含至少一种miRNA，并且通过使两种同种异体白细胞群体接触获得，其中两种群体中的至少一种用低免疫原性生物相容性聚合物修饰。还提供了无细胞致耐受性组合物，制备这种组合物的方法以及这些组合物的治疗用途。

4. 发明申请

WO2012030636A1 SAMPLE HOLDER FOR DYNAMIC LIGHT SCATTERING 审中-公开
标题翻译：动态光散射样品座
公开(公告)号：WO2012030636A1
公开(公告)日：2012-03-08
申请号：PCT/US2011/049271
申请日：2011-08-26
申请人： CANADIAN BLOOD SERVICES , MAURER, Elisabeth , MAURER, Georg , BROWN, Keddie , BOURNE, Gyasi , MACCALLUM, Kenneth , CHARLEBOIS, Paul
发明人： MAURER, Elisabeth , MAURER, Georg , BROWN, Keddie , BOURNE, Gyasi , MACCALLUM, Kenneth , CHARLEBOIS, Paul
IPC分类号： B01L3/00 , F25B29/00 , G01N21/00
CPC分类号： G01N21/0332 , G01N15/0211 , G01N21/15 , G01N21/51 , G01N2015/0065 , G01N2015/0084 , G01N2015/0222 , G01N2021/513 , Y10T436/101666
摘要： There is described a sample holder and associated fluid container assembly for optical analysis of a fluid sample within a translucent container of the fluid container assembly. The sample holder includes clamping members rotatably mounted to a frame for rotation, about parallel axes spaced apart from each other, between a container accepting position in which the clamping members are spaced apart from the translucent container, and an analysis position in the clamping members abut the translucent container. The clamping members each define an optical waveguide slot extending therethrough that is substantially aligned with the translucent container when the clamping members are disposed in the analysis position, to thereby provide optical access to the translucent container for optical analysis of the fluid sample therein.
摘要翻译：描述了用于在流体容器组件的半透明容器内的流体样品的光学分析的样品保持器和相关联的流体容器组件。样品架包括夹紧构件，夹紧构件可旋转地安装到框架上，围绕彼此间隔开的平行轴线，在夹持构件与半透明容器间隔开的容器接收位置之间以及夹紧构件中的分析位置抵接半透明的容器。夹紧构件各自限定了延伸穿过其中的光波导槽，当将夹紧构件设置在分析位置时，该光波导狭缝基本上与半透明容器对准，从而提供对半透明容器的光学通路，以便对其中的流体样品进行光学分析。

5. 发明申请

WO2007140059A2 HIGH MOLECULAR WEIGHT CHELATION STRUCTURE 审中-公开
标题翻译：高分子重量结构
公开(公告)号：WO2007140059A2
公开(公告)日：2007-12-06
申请号：PCT/US2007067179
申请日：2007-04-23
申请人： CANADIAN BLOOD SERVICES , SCOTT MARK D , KIZHAKKEDATHU JAYACHANDRAN N
发明人： SCOTT MARK D , KIZHAKKEDATHU JAYACHANDRAN N
IPC分类号： A61K31/785 , C08G63/48 , C08G63/91
CPC分类号： A61K31/785 , A61K47/58 , A61K47/60
摘要： A chelation structure and method of forming and using the chelation structure. The chelation structure has a backbone that includes a linear sequence of monomeric backbone units, at least one polymer side chain, and at least one chelator side chain. The side chains are each covalently coupled to the backbone at one of the monomeric backbone units by a bond that is independently biodegradable or non-biodegradable. The chelation structure is synthesized by Radical Addition Fragmentation Transfer (RAFT), Atom Transfer Radical Polymerization (ATRP), or Free Radical Polymerization (FRP). The chelation structure, individually or in combination with a shuttle chelator, may be introduced into a mammal to bind an amount of a substance in a mammal, the substance being at least one of a metal and heme. The chelation structure has a log stability constant exceeding that of the shuttle chelator for binding the substance within cells of the mammal.
摘要翻译：一种螯合结构和形成和使用螯合结构的方法。螯合结构具有主链，其包括单体主链单元，至少一个聚合物侧链和至少一个螯合剂侧链的线性序列。侧链通过单独的可生物降解或不可生物降解的键共价偶联到单体主链单元之一的骨架上。螯合结构通过自由基加成转移（RAFT），原子转移自由基聚合（ATRP）或自由基聚合（FRP）合成。螯合结构单独地或与穿梭螯合剂组合可以引入到哺乳动物中以结合一定量的哺乳动物物质，该物质是金属和血红素中的至少一种。螯合结构的对数稳定性常数超过用于结合哺乳动物细胞内的物质的穿梭螯合剂的对数稳定性。

6. 发明申请

WO2005007843B1 AMINO ACID-SUBSTITUTED COAGULATION FACTOR V 审中-公开
标题翻译：氨基酸取代的凝血因子V
公开(公告)号：WO2005007843B1
公开(公告)日：2005-11-17
申请号：PCT/CA2004001089
申请日：2004-07-23
申请人： CANADIAN BLOOD SERVICES , PRYZDIAL EDWARD L G , ZEIBDAWI ABED , GRUNDY JEAN
发明人： PRYZDIAL EDWARD L G , ZEIBDAWI ABED , GRUNDY JEAN
IPC分类号： C12N9/64 , A61K38/17 , C07K14/745 , C12Q1/37
CPC分类号： C12N9/647 , A61K38/00
摘要： There is provided FV derivatives that reduce blood clotting activity, by reducing thrombin generation, when compared to wild-type FV. In particular, the FV of the present invention comprises single-point and multi-point mutations, encompassed by aspartic acid 79 to glutamic acid 119. The derivatives can be used to treat patient with conditions necessitating reduced clotting activity.
摘要翻译：提供了与野生型FV相比通过减少凝血酶生成来降低凝血活性的FV衍生物。具体而言，本发明的FV包含单点和多点突变，由天冬氨酸79包含谷氨酸119.该衍生物可用于治疗具有需要降低的凝血活性的病症的患者。

7. 发明申请

WO2005007843A3 AMINO ACID-SUBSTITUTED COAGULATION FACTOR V 审中-公开
标题翻译：氨基酸取代凝血因子V
公开(公告)号：WO2005007843A3
公开(公告)日：2005-09-29
申请号：PCT/CA2004001089
申请日：2004-07-23
申请人： CANADIAN BLOOD SERVICES , PRYZDIAL EDWARD L G , ZEIBDAWI ABED , GRUNDY JEAN
发明人： PRYZDIAL EDWARD L G , ZEIBDAWI ABED , GRUNDY JEAN
IPC分类号： C12N9/64 , A61K38/17 , C07K14/745 , C12Q1/37
CPC分类号： C12N9/647 , A61K38/00
摘要： There is provided FV derivatives that reduce blood clotting activity, by reducing thrombin generation, when compared to wild-type FV. In particular, the FV of the present invention comprises single-point and multi-point mutations, encompassed by aspartic acid 79 to glutamic acid 119. The derivatives can be used to treat patient with conditions necessitating reduced clotting activity.
摘要翻译：与野生型FV相比，提供FV衍生物，通过降低凝血酶产生，降低血液凝固活性。特别地，本发明的FV包括天冬氨酸79至谷氨酸119所包含的单点和多点突变。该衍生物可用于治疗需要降低凝血活性的病人。

8. 发明申请

WO2005075496A1 A METHOD FOR THE SIMULTANEOUS DETERMINATION OF BLOOD GROUP AND PLATELET ANTIGEN GENOTYPES 审中-公开
标题翻译：血液组和血小板抗原基因组同时测定的方法
公开(公告)号：WO2005075496A1
公开(公告)日：2005-08-18
申请号：PCT/CA2005/000250
申请日：2005-02-07
申请人： CANADIAN BLOOD SERVICES , DENOMME, Gregory A.
发明人： DENOMME, Gregory A.
IPC分类号： C07H21/00
CPC分类号： C12Q1/6881 , C07H21/00 , C07H21/04 , C12Q2600/156 , C12Q2600/16
摘要： RBC and platelet (Plt) alloimmunization requires antigen-matched blood to avoid adverse transfusion reactions. Some blood collection facilities use unregulated Abs to reduce the cost of mass screening, and later confirm the phenotype with government approved reagents. Alternatively, RBC and Plt antigens can be screened by virtue of their associated single nucleotide polymorphisms (SNPs). We developed a multiplex PCR-oligonucleotide extension assay using the GenomeLab SNPStream platform to genotype blood for a plurality of blood group antigen-associated SNPs, including but not limited to: RhD (2), RhC/c, RhE/e, S/s, K/k, Kp a/b , Fya/b, FY0, Jk a/b , Di a/b , and HPA-1a/b.
摘要翻译： RBC和血小板（Plt）同种异体免疫需要抗原匹配的血液，以避免不良的输血反应。一些采血设施使用不受管制的Abs来降低大规模筛查的成本，并且随后用政府批准的试剂确认表型。或者，可以通过其相关联的单核苷酸多态性（SNP）筛选RBC和Plt抗原。我们使用GenomeLab SNPStream平台开发了多重PCR-寡核苷酸延伸测定法，以将多个血型抗原相关SNP的血型基因分型，包括但不限于：RhD（2），RhC / c，RhE / e，S / s ，K / k，Kp ，Fya / b，FY0，Jk ，Di 和HPA-1a / b。

9. 发明申请

WO0144490A3 A NOVEL METHOD TO PRODUCE HUMAN NATURAL INTERFERON- alpha 审中-公开
标题翻译：一种生产人类自然干扰素α的新方法
公开(公告)号：WO0144490A3
公开(公告)日：2001-11-29
申请号：PCT/CA0001479
申请日：2000-12-12
申请人： HEMA QUEBEC , CANADIAN BLOOD SERVICES , LEMIEUX REAL , NERON SONIA , PROULX CHANTAL
发明人： LEMIEUX REAL , NERON SONIA , PROULX CHANTAL
IPC分类号： A61K38/00 , C07K14/56 , A61K38/21
CPC分类号： C07K14/56 , A61K38/00
摘要： The present invention relates to a novel method for producing human natural interferon- alpha using ex vivo expanded cord blood hematopoietic cells, on a large scale.
摘要翻译：本发明涉及使用离子扩增脐带血造血细胞大规模生产人天然干扰素-α的新方法。

10. 发明申请

WO2016004538A1 COMBINATION THERAPY OF A CELLULAR PRO-TOLEROGENIC AND PRO-INFLAMMATORY PREPARATIONS FOR MODULATING THE IMMUNE SYSTEM 审中-公开
标题翻译：用于调节免疫系统的细胞预耐性和预防性制剂的组合治疗
公开(公告)号：WO2016004538A1
公开(公告)日：2016-01-14
申请号：PCT/CA2015/050647
申请日：2015-07-10
申请人： CANADIAN BLOOD SERVICES
发明人： SCOTT, Mark D. , WANG, Duncheng , TOYOFUKU, Wendy M.
IPC分类号： A61K35/15 , A61P37/02 , C12N5/078
CPC分类号： A61K35/16 , A61K31/713 , A61K35/15 , A61K39/0008 , A61K2039/545 , A61K2039/577 , C12N5/0006 , C12N5/0639 , C12N5/064 , C12N5/0648 , C12N15/113 , C12N2310/141 , C12N2533/30
摘要： This disclosure relates to a cellular-based therapies for modulating the level of regulatory T cells (Treg) and/or the level of pro-inflammatory T cells (Th17/Th1). To provide these therapeutic effects, a combination comprising at least one a cellular pro-tolerogenic preparation and at least one a cellular pro-inflammatory preparation are administered sequentially.
摘要翻译：本公开涉及用于调节调节性T细胞（Treg）水平和/或促炎T细胞（Th17 / Th1）水平的基于细胞的疗法。为了提供这些治疗效果，依次施用包含至少一种细胞耐受性制剂和至少一种细胞促炎症制剂的组合。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式